Clinical Trial Update: Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer [Phase 3]

View source ↗

Summary

This document outlines the safety monitoring protocol for a 200 mg dose of bicalutamide in patients with advanced prostate cancer in a Phase 3 trial. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• bicalutamide (bicalutamide)

Snippet

Sponsor: AstraZeneca | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED